<DOC>
	<DOCNO>NCT01645046</DOCNO>
	<brief_summary>The purpose study evaluate lipid lowering effect clinical safety natural hypolipidemic compound , coenzyme A （CoA） capsule Chinese patient moderate dyslipidemia .</brief_summary>
	<brief_title>The Effects Coenzyme A Serum Lipids Patients With Hyperlipidemia</brief_title>
	<detailed_description>Hyperlipidemia play important role development progression atherosclerosis . Modulating lipid level show reduce development atherosclerosis incidence cardiovascular disease . The HMG-CoA reductase inhibitor ( also know statin ) effective agent available management hyperlipidemia prevention major cardiovascular event . Although statin base therapy commonplace primary secondary prevention , several economical , clinical safety issue raise , ongoing research new , safer effective agent use alone combination exist cardiovascular drug . Coenzyme A ( CoA ) ubiquitous essential cofactor play central role metabolism carboxylic acid , include short- long-chain fatty acid , well carbohydrate protein . In metabolic pathway lipid , CoA participate fatty acid β-oxidation , promote triglyceride ( TG ) catabolism . Previous research reveal insufficiency CoA vivo influence fatty acid β-oxidation catabolism impaired clearance TG plasma , suppose one plausible reason result type Ⅱb Ⅳ hyperlipoproteinemia . In addition , epidemiological study show prevalence serum lipid level increase age , may relate reduction CoA synthesis age individual . Moreover , study animal give evidence prove supplement CoA normalizing activity plasma lipid dyslipidemia . Pantethine versatile well tolerated hypolipidemic agent decrease serum triglyceride , LDL cholesterol , apolipoprotein B , increase HDL cholesterol apolipoprotein A-I . Pantethine disulfide pantetheine per se occur naturally product coenzyme A catabolism . Theoretically , antihyperlipidemia effect CoA directly effectively pantethine . Researches rabbit rat model prove high dose CoA orally relieve fast hyperlipidemia insulin resistance induce high fat diet . So far sufficient clinical research data support efficacy CoA dyslipidemia patient . The present study show , first time , safety , effectiveness oral CoA .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperlipoproteinemias</mesh_term>
	<criteria>TG 2.3～6.5mmol/l meeting China National Cholesterol Education Programme diagnostic criterion hyperlipidemia . 1 . TC &gt; 7.5 mmol/l LDLC &gt; 3.6 mmol/l 2 . Body Mass Index &gt; 30 kg/m2 3. drug induce secondary hypercholesterolemia ( dibenzothiazine , contraceptive agent adrenal cortex hormone ) 4. pregnancy 5. acute coronary syndrome , acute myocardial infarction undergone revascularization procedure within 6 month 6. acute liver disease hepatic dysfunction , determine level alanine aminotransferase ( ALT ) aspartate aminotransferase level ( AST ) 3fold upper normal limit 7. nephrotic syndrome serum creatinine ( Cr ) ( ≥179 µmol/L ) creatine phosphokinase ( CK ) 3fold upper normal limit 8. primary hypothyroidism 9. psychiatric patient HIVinfected patient 10. poorly control hypertension , indicate Systolic Blood Pressure &gt; 180 mmHg Diastolic Blood Pressure &gt; 110 mmHg 11 . Type I diabetes mellitus（DM） , poorly control Type II DM ( BS &gt; 11.0 mmol/L ) Type II DM LDLC &gt; 2.6 mmol/L.Patients use immunosuppressive drug , prohibit medication lipidlowing drug also exclude . Subjects also ineligible study severe disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>